SBIR/STTR Research Award

FISH Assay for Acute Myeloid Leukemia

Award identifier 15335164e08612f245eb8e99ba4b4f94ef62a65c22140064335a461ce3562526Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$226,508

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Gentris Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Applicant's abstract): The goal of this research is to develop two fluorescence in situ hybridization (FISH) assays for detecting the t(8;21)(q22;q22) and inv(16)(p13q22) and related t(16;16)(p13;q22) translocations found in two different subsets of acute myeloid leukemia (AML), M2 and M4Eo, respectively. These cancers are traditionally treated by chemotherapy; however, many patients relapse and become refractory to treatment. Diagnosis and post treatment follow-up are currently performed by karyotype, Southern blotting or PCR. These methods, however, have limitations in specificity and/or sensitivity. A precise, reliable and simple method for detecting cancer cells, especially in post-treatment specimens, is needed. FISH is an improvement over current methods used for detecting translocations; however, no clinically tested probes are available for detecting AML. This SBIR proposal aims to develop novel, sensitive and specific FISH assays that will unambiguously detect translocation carrying nuclei in diagnostic and follow up patient samples. PROPOSED COMMERCIAL APPLICATION: The proposed research will provide highly specific and sensitive FISH assays for detecting chromosomal translocations present in Acute Myeloid Leukemia (AML) for use in cancer cytogenetic reference laboratories.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.